
Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)

217-9197 (toll free).

Reviewer: markspencer

Timestamp: Tue Jul 10 12:02:09 EDT 2007

Validated By CRFValidator v 1.0.2

Application No: 10591040 Version No: 1.0

Input Set:

Output Set:

Started: 2007-07-09 15:49:13.986

Finished: 2007-07-09 15:49:14.335

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 349 ms

Total Warnings: 2

Total Errors: 0

No. of SeqIDs Defined: 2

Actual SeqID Count: 2

Error code		Error Description												
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(1)			
W	213	Artificial	or	IInknown	found	in	<213>	in	SEO	TD	(2)			

SEQUENCE LISTING

```
<110> F. Hoffmann-La Roche AG
<120> Method for the purification of an N-terminal fragment of
       hepatocyte growth factor
<130> 22389 WO
<140> 10591040
<141> 2007-07-09
<150> EP 04004950.4
<151> 2004-03-03
<160> 2
<170> PatentIn version 3.2
<210> 1
<211> 1350
<212> DNA
<213> Artificial
<220>
<223> dna coding for NK4
<220>
<221> CDS
<222> (1)..(1350)
<400> 1
                                                                       48
atg tct cgt aaa cgt cgt aat act att cat gaa ttc aaa aaa tca gca
Met Ser Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala
                                    10
                                                        15
1
aag act acc cta atc aaa ata gat cca gca ctg aag ata aaa acc aaa
                                                                       96
Lys Thr Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys
            20
                                25
                                                     30
aaa gtg aat act gca gac caa tgt gct aat aga tgt act agg aat aaa
                                                                     144
Lys Val Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys
        35
                                                45
                            40
gga ctt cca ttc act tgc aag gct ttt gtt ttt gat aaa gca aga aaa
                                                                     192
Gly Leu Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys
    50
                        55
                                            60
                                                                     240
caa tgc ctc tgg ttc ccc ttc aat agc atg tca agt gga gtg aaa aaa
Gln Cys Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys
                                        75
                                                             80
65
                    70
                                                                     288
gaa ttt ggc cat gaa ttt gac ctc tat gaa aac aaa gac tac att aga
Glu Phe Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg
                85
                                                         95
                                    90
```

		atc Ile															336
		agt Ser 115															384
		agc Ser														2	132
		tgt Cys														2	180
		aat Asn			_	_				_							528
		gtt Val															576
		cat His 195														(624
		cac His														(672
		gat Asp														-	720
		act Thr														-	768
	_	gct Ala	_							_	Ī		_	_		{	316
	_	tgc Cys 275						_						_		}	364
		tgg Trp					_	_	_				_			9	912
		cat His														9	960
gaa	aat	tac	tgc	cga	aat	cca	gat	ggg	tct	gaa	tca	ccc	tgg	tgt	ttt	10	800

Glu	Asn	Tyr	Cys	Arg 325	Asn	Pro	Asp	Gly	Ser 330	Glu	Ser	Pro	Trp	Cys 335	Phe	
				aac Asn		_	_									1056
tgt Cys																1104
tat Tyr				tta Leu									_			1152
tgg Trp 385	Asp	Lys	Asn		Glu	Asp	Leu	His	Arg	His	Ile					1200
gat Asp	_	_	_	_					_	_			_	_	_	1248
gct Ala																1296
tat Tyr				tct Ser	_	_			Ī							1344
taa	tag															1350
<210<211<212<213	> 4 > E	148 PRT	Ēiciā	al												
<220 <223		orot∈	ein-s	seque	ence	of 1	1K4									
< 400)> 2	2														
Met 1	Ser	Arg	Lys	Arg 5	Arg	Asn	Thr	Ile	His 10	Glu	Phe	Lys	Lys	Ser 15	Ala	
Lys	Thr	Thr	Leu 20	Ile	Lys	Ile	Asp	Pro 25	Ala	Leu	Lys	Ile	Lys 30	Thr	Lys	
Lys	Val	Asn 35	Thr	Ala	Asp	Gln	Cys	Ala	Asn	Arg	Cys	Thr 45	Arg	Asn	Lys	

Gly Leu Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys

Gln Cys Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys
65 70 75 80

50

Glu Phe Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg 85 90 95

Asn Cys Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile
100 105 110

Thr Lys Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His
115 120 125

Glu His Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu 130 135 140

Asn Tyr Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe
145 150 150 155 160

Thr Ser Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys
165 170 175

Ser Glu Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu 180 185 190

Met Asp His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln
195 200 205

Phe Asp Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp 225 230 230 235 235 240

Cys Tyr Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys 245 250 255

Thr Cys Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr 260 270

Thr Glu Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn 275 280 285

Thr Ile Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu Asn Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr Thr Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr Met Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp Ala Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp Asp Ala His Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr Ile Val